TrumpI haven't heard a front runner yet but the pick is coming soon. Whoever the pick is, he will clearly be mandated to start swinging the axe. Now that the path forward has less resistance, the team has to get this right.
There is absolutely no question that big pharma is watching this very closely. The feeling is that they would rather overpay once they see the results than buy TLT now. If I were one of them, no question that I would take the company out now because the therapeutic division will grow into the transaction price they would pay now and then you don't risk losing a bidding war.